Evidence map›Paper›PMID 40224142›Full record

ArticleMethodsX2025

Positive nutritional selection of adults with healthy lifestyle and high daily fiber consumption for the isolation of beneficial intestinal bacteria: The iTARGET cohort study protocol.

Aurélie Caille, Chloé Connan, Noelle Lyon Belgy, Elise Borezée, Claire Cherbuy, Nathalie Meunier, Victoria Meslier

Registry-linked trialAbstract read
In one paragraph

Article in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06166810 (In Silico and in Vitro Targeting of Healthy Gut Bacteria With Fiber Degrading Metabolic Potential), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06166810 recruitingnot on this map

In Silico and in Vitro Targeting of Healthy Gut Bacteria With Fiber Degrading Metabolic Potential

Typeobservational_patient_registrySponsorInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRan2023 to 2026Enrolled10ConditionsGeneral Population
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aurélie CailleCentre Hospitalier Universitaire de Clermont-Ferrand, CRNH Auvergne, Clermont-Ferrand, France.
Chloé ConnanUniversité Paris-Saclay, INRAE, MetaGenoPolis, 78350 Jouy-en-Josas, France.
Noelle Lyon BelgyCentre Hospitalier Universitaire de Clermont-Ferrand, CRNH Auvergne, Clermont-Ferrand, France.
Elise BorezéeUniversité Paris-Saclay, INRAE, MetaGenoPolis, 78350 Jouy-en-Josas, France.
Claire CherbuyUniversité Paris-Saclay, INRAE, Micalis, 78350 Jouy-en-Josas, France.
Nathalie MeunierCentre Hospitalier Universitaire de Clermont-Ferrand, CRNH Auvergne, Clermont-Ferrand, France.
Victoria MeslierUniversité Paris-Saclay, INRAE, MetaGenoPolis, 78350 Jouy-en-Josas, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in the study of the gut microbiota has pointed to its under-utilized source of potentially beneficial bacteria, known as next generation probiotics, offering a promising avenue to restore or compensate impaired gut microbiota toward a healthy state. Aside from the difficulties to achieve in-lab adequate culture conditions, the use of beneficial bacterial isolates is also limited by their bioavailability in the donor itself. In the iTARGET study, we positively selected donors based on their diet enriched in fiber, that has been shown to increase the prevalence of bacterial species associated with health. The iTARGET study is a monocenter, prospective, observational study of adults with healthy lifestyle and high daily fiber consumption. We aim to recruit individuals in two phases, the first one for all individuals that will permit the identification of carriers for bacteria of interest and the second phase for a subset of individuals to allow for culture and isolation of previously identified potentially beneficial bacteria. Our primary outcome is the isolation and culture of at least one potentially beneficial isolate. The secondary outcomes comprised the high throughput metagenomic profiles of the intestinal microbiota and the characterization of the cultured isolates. The study was approved by the French Research Ethics Committees (Comité de Protection des Personnes Sud-Est I) under the National reference ID 2023-A01677-38. Study findings and results will be published in peer-reviewed Open Access journals. (Trial registration number on ClinicalTrials.gov: NCT06166810).

Indexed as

CulturomicsGut microbiotaNext-generation probioticsNutritionObservational cohortShotgun metagenomics

Identifiers

PMID40224142
PMCPMC11987684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.